$355 Million is the total value of Parkman Healthcare Partners LLC's 79 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXNX | AXONICS MODULATION TECHNOLOG | $8,493,000 | +38.2% | 241,909 | 0.0% | 2.39% | -16.0% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $7,640,000 | +38.3% | 300,805 | 0.0% | 2.15% | -16.0% | |
| XENE | XENON PHARMACEUTICALS INC | $7,402,000 | +10.6% | 590,267 | 0.0% | 2.08% | -32.8% | |
| ICAD | ICAD INC | $7,249,000 | +36.1% | 725,590 | 0.0% | 2.04% | -17.3% | |
| MTEM | MOLECULAR TEMPLATES INC | $4,728,000 | +3.8% | 342,875 | 0.0% | 1.33% | -36.9% | |
| KOD | KODIAK SCIENCES INC | $3,530,000 | +13.5% | 65,218 | 0.0% | 0.99% | -31.1% | |
| SPNE | SEASPINE HLDGS CORP | $2,573,000 | +28.1% | 245,785 | 0.0% | 0.72% | -22.1% | |
| BBIO | BRIDGEBIO PHARMA INC | $2,453,000 | +12.5% | 75,215 | 0.0% | 0.69% | -31.7% | |
| NEPH | NEPHROS INC | $2,109,000 | +33.1% | 251,366 | 0.0% | 0.59% | -19.1% | |
| CBIO | CATALYST BIOSCIENCES INC | $1,263,000 | +34.2% | 215,237 | 0.0% | 0.36% | -18.3% | |
| CATABASIS PHARMACEUTICALS IN | $1,000,000 | +55.0% | 155,473 | 0.0% | 0.28% | -5.7% | ||
| MBIO | MUSTANG BIO INC | $965,000 | +18.7% | 303,376 | 0.0% | 0.27% | -27.9% | |
| CLPT | CLEARPOINT NEURO INC | $89,000 | -1.1% | 25,078 | 0.0% | 0.02% | -40.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DEXCOM INC | 16 | Q3 2023 | 6.3% |
| ACLARIS THERAPEUTICS INC | 16 | Q3 2023 | 10.0% |
| XENON PHARMACEUTICALS INC | 16 | Q3 2023 | 3.3% |
| NATERA INC | 16 | Q3 2023 | 3.4% |
| AVID BIOSERVICES INC | 15 | Q3 2023 | 2.9% |
| SCHRODINGER INC | 15 | Q3 2023 | 4.2% |
| REPRO MED SYS INC | 15 | Q2 2023 | 2.0% |
| MANNKIND CORP | 15 | Q3 2023 | 1.6% |
| IQVIA HLDGS INC | 14 | Q1 2023 | 4.6% |
| INSULET CORP | 14 | Q3 2023 | 2.9% |
View Parkman Healthcare Partners LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PLUS THERAPEUTICS, INC. | February 13, 2023 | 583,467 | 1.7% |
View Parkman Healthcare Partners LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Parkman Healthcare Partners LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.